Market Overview

UPDATE: Cantor Fitzgerald Raises PT to $13 on Synergy Pharmaceuticals on Positive Data

Related SGYP
More Pharma Deals In The Pipeline?
Synergy Pharmaceuticals Offers Update On Ongoing Irritable Bowel Syndrome With Constipation Program
John Paulson Trims Synergy (GuruFocus)

Cantor Fitzgerald reiterated its Buy rating on Synergy Pharmaceuticals (NASDAQ: SGYP) and increased its price target from $7 to $13.

Cantor Fitzgerald commented, "Positive data announcement is a key catalyst: Synergy announced positive top-line results from its Phase IIb/III chronic constipation (CC) trial of plecanatide. While details were not disclosed since the company is attempting to present late-breaker data at DDW, management indicated that (1) there was a nice dose response effect; and (2) the highest dose in the trial (3 mg) demonstrated a 19% responder rate versus 10.7% for placebo, which was statistically significant (p=0.009)."

Synergy Pharmaceuticals closed at $5.26 on Monday.

Latest Ratings for SGYP

May 2016Rodman & RenshawMaintainsBuy
Mar 2016Rodman & RenshawMaintainsBuy
Mar 2016CitigroupMaintainsNeutral

View More Analyst Ratings for SGYP
View the Latest Analyst Ratings

Posted-In: Cantor FitzgeraldAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (SGYP)

View Comments and Join the Discussion!